Teva Pharmaceutical Industries Limited announced the Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving the company. Teva has initiated a search to identify its next head of Global R&D. Dr. Fridriksdottir plans to remain in her role until June 20, 2022 to assist with a smooth transition.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.98 USD | -0.71% | +5.51% | +33.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.91% | 15.95B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited Announces Leaving of Hafrun Fridriksdottir, Executive Vice President, Global R&D, Effective June 20, 2022